Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics.
| Autor: | Eshghi A; From the College of Osteopathic Medicine, Kansas City University, Joplin, MO., Covington MF; Department of Radiology and Imaging Sciences, University of Utah, Center for Quantitative Cancer Imaging, Huntsman Cancer Institute, Salt Lake City, UT., Eshghi N; Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR., Kuo PH; Departments of Medical Imaging, Medicine, and Biomedical Engineering, University of Arizona, Tucson, AZ. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical nuclear medicine [Clin Nucl Med] 2022 Jun 01; Vol. 47 (6), pp. 488-495. Date of Electronic Publication: 2022 Apr 05. |
| DOI: | 10.1097/RLU.0000000000004196 |
| Abstrakt: | Abstract: The majority of aggressive prostate cancers overexpress the transmembrane protein prostate-specific membrane antigen (PSMA). PSMA is, therefore, an attractive target for drug development. Over the last decade, numerous PSMA-targeted radiopharmaceuticals for imaging and therapy have been developed and investigated in theranostic combination. PSMA-targeted radiopharmaceuticals for imaging have been primarily developed for PET. PSMA PET provides whole-body evaluation of the degree of PSMA expression on tumors and potentially provides a method to better select patients for PSMA-targeted therapy. Numerous PSMA-targeted therapeutic agents using β- or α-particle emitters are under study in clinical trials. In particular, the β-particle-emitting radioisotope 177Lu bound to PSMA-targeted small molecules have ongoing and completed late-stage clinical trials in metastatic castration-resistant prostate cancer. To define the most appropriate patient group for PSMA-targeted therapeutics, multiple studies have investigated PSMA and FDG PET/CT to establish PET parameters as predictive and prognostic biomarkers. This article discusses recent clinical trials that examine the optimal use of PET for the selection of patients for PSMA-targeted therapeutics and provides an integrative overview of choice of PET tracer(s), targeting molecule, therapeutic radioisotope, nonradioactive therapy, and cancer type (prostate or nonprostate). Competing Interests: Conflicts of interest and sources of funding: none declared. M.C. is a consultant for Invicro, LLC for medical imaging review, outside of the scope of this project. P.H.K. is an employee of Invicro. He is a consultant and/or speaker for Amgen, Eisai, General Electric Healthcare, Novartis, Invicro, Bayer, Chimerix, Fusion Pharma, and UroToday. He is a recipient of research grants from Blue Earth Diagnostics and General Electric Healthcare. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|